Dietary resveratrol does not delay engraftment, sensitize to vincristine or inhibit growth of high-risk acute lymphoblastic leukemia cells in NOD/SCID mice

International Journal of Oncology

Volumn 41, Issue 6, 2012, Pages 2207-2212

  Zunino, Susan J ^a   Storms, David H ^a   Newman, John W ^a   Pedersen, Theresa L ^a   Keen, Carl L ^b   Ducore, Jonathan M ^c  

^a AGRICULTURAL RESEARCH SERVICE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute lymphoblastic leukemia; Dietary resveratrol; NOD SCID mice

Indexed keywords

CD19 ANTIGEN; RESVERATROL; VINCRISTINE;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD; CANCER GROWTH; CANCER SURVIVAL; CELL GROWTH; CELL SURVIVAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG EFFICACY; DRUG SENSITIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; LEUKEMIA CELL; LYMPHATIC LEUKEMIA; MASS SPECTROMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT DURATION; TUMOR ENGRAFTMENT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BODY WEIGHT; CELL LINE, TUMOR; DIET; FEMALE; GLUCURONIDES; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; NEOPLASM TRANSPLANTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; STILBENES; SULFATES; TUMOR BURDEN; VINCRISTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84869800973     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1650     Document Type: Article

References (38)

1. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, et al: Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res 24: 2783-2840, 2004. (Pubitemid 39409568)
2. Banerjee S, Bueso-Ramos C and Aggarwal BB: Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-κB, cyclooxygenase 2, and matrix metalloproteinase 9. Cancer Res 62: 4945-4954, 2002. (Pubitemid 34984418)
3. Li ZG, Hong T, Shimada Y, Komoto I, Kawabe A, et al: Suppression of N-nitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis 23: 1531-1536, 2002. (Pubitemid 35012434)
4. Lee EO, Lee HJ, Hwang HS, Ahn KS, Chae C, et al: Potent inhibition of Lewis lung cancer growth by heyneanol A from the roots of Vitis amurensis through apoptotic and anti-angiogenic activities. Carcinogenesis 27: 2059-2069, 2006. (Pubitemid 44530581)
5. Liu HS, Pan CE, Yang W and Liu XM: Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. World J Gastroenterol 9: 1474-1476, 2003. (Pubitemid 36992335)
6. Tessitore L, Davit A, Sarotto I and Caderni G: Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 21: 1619-1622, 2000. (Pubitemid 30608219)
7. Gupta SC, Kannappan R, Reuter S, Kim JH and Aggarwal BB: Chemosensitization of tumors by resveratrol. Ann NY Acad Sci 1215: 150-160, 2011.
8. Colin D, Limagne E, Jeanningros S, Jacquel A, Lizard G, et al: Endocytosis of resveratrol via lipid rafts and activation of downstream signaling pathways in cancer cells. Cancer Prev Res 4: 1095-1106, 2011.
9. Li G, He S, Chang L, Lu H, Zhang H, et al: GADD45α and annexin A1 are involved in the apoptosis of HL-60 induced by resveratrol. Phytomedicine 18: 704-709, 2011.
10. Kartal M, Saydam G, Sahin F and Baran Y: Resveratrol triggers apoptosis through ceramide metabolizing genes in human K562 chronic myeloid leukemia cells. Nutr Cancer 63: 637-644, 2011.
11. Faderl S, Kantarjian HM, Talpaz M and Estrov Z: Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 91: 3995-4019, 1998. (Pubitemid 28261960)
12. Greaves MF and Wiemels J: Origins of chromosome translocations in childhood leukaemia. Nat Rev 3: 1-11, 2003.
13. Greil J, Gramatzki M, Burger R, Marschalek R, Peltner M, et al: The acute lymphoblastic leukaemia cell line SEM with t(4;11) chromosomal rearrangement is biphenotypic and responsive to interleukin-7. Br J Haematol 86: 275-283, 1994. (Pubitemid 24198988)
14. Stong RC, Korsmeyer SJ, Parkin JL, Arthur DC and Kersey JH: Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood 65: 21-31, 1985. (Pubitemid 15191033)
15. Lange B, Valtieri M, Santoli D, Caracciolo D, Mavilio F, et al: Growth factor requirements of childhood acute leukemia: establishment of GM-CSF-dependent cell lines. Blood 70: 192-199, 1987. (Pubitemid 17111261)
16. Baersch G, Mollers T, Hotte A, Dockhorn-Dworniczak B, Rube C, et al: Good engraftment of B-cell precursor ALL in NOD-SCID mice. Klin Padiatr 209: 178-185, 1997. (Pubitemid 27328966)
17. Borgmann A, Baldy C, von Stackelberg A, Beyermann B, Fichtner I, et al: Childhood ALL blasts retain phenotypic and genotypic characteristics upon long-term serial passage in NOD/SCID mice. Pediatr Hematol Oncol 17: 635-650, 2000.
18. Liem NLM, Papa RA, Milross CG, Schmid MA, Tajbakhsh M, et al: Characterization of childhood acute lymphoblastic leukemia xenograft models for the preclinical evaluation of new therapies. Blood 103: 3905-3914, 2004. (Pubitemid 38596312)
19. Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, et al: The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 99: 4100-4108, 2002. (Pubitemid 35332053)
20. Nijmeijer BA, Mollevanger P, van Zelderen-Bhola SL, Kluin-Nelemans HC, Willemze R, et al: Monitoring of engraftment and progression of acute lymphoblastic leukemia in individual NOD/SCID mice. Exp Hematol 29: 322-329, 2001. (Pubitemid 32220124)
21. Dörrie J, Gerauer H, Wachter Y and Zunino SJ: Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res 61: 4731-4739, 2001. (Pubitemid 32691883)
22. Dörrie J, Sapala K and Zunino SJ: Carnosol-induced apoptosis and downregulation of Bcl-2 in B-lineage leukemia cells. Cancer Lett 170: 33-39, 2001. (Pubitemid 32607658)
23. Kellner C and Zunino SJ: Nitric oxide is synthesized in acute leukemia cells after exposure to phenolic antioxidants and initially protects against mitochondrial membrane depolarization. Cancer Lett 215: 43-52, 2004. (Pubitemid 39221457)
24. Nachman JB, Sather HN, Sensel MG, Trigg ME, Cherlow JM, et al: Augmented post-induction therapy for children with high- risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med 338: 1663-1671, 1998. (Pubitemid 28267911)
25. Crowell JA, Korytko PJ, Morrissey RL, Booth TD and Levine BS: Resveratrol-associated renal toxicity. Toxicol Sci 82: 614-619, 2004. (Pubitemid 39600090)
26. Zunino SJ, Storms DH and Ducore JM: Novel in vivo model of inducible multi-drug resistance in acute lymphoblastic leukemia with chromosomal translocation t(4;11). Cancer Lett 296: 49-54, 2010.
27. Zunino SJ, Storms DH, Newman JW, Pedersen TL, Keen CL and Ducore JM: Resveratrol given intraperitoneally does not inhibit the growth of high-risk t(4;11) acute lymphoblastic leukemia cells in a NOD/SCID mouse model. Int J Oncol 40: 1277-1284, 2012.
28. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, et al: Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics, and effect on the insulin-like growth factor axis. Cancer Res 70: 9003-9011, 2010.
29. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, et al: Clinical trials of resveratrol. Ann NY Acad Sci 1215: 161-169, 2011.
30. Walle T, Hsieh F, De Legge MH, Oatis JE and Walle UK: High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 32: 1377-1382, 2004. (Pubitemid 39564557)
31. Vitrac X, Desmouliere A, Brouillaud B, Krisa S, Deffieux G, et al: Distribution of [14C]-trans-resveratrol, a cancer chemopreventive polyphenol, in mouse tissues after oral administration. Life Sci 72: 2219-2233, 2003. (Pubitemid 36292144)
32. Wenzel E, Soldo T, Erbersdobler H and Somoza V: Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res 49: 482-494, 2005. (Pubitemid 40780395)
33. Baur JA and Sinclair DA: Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 5: 493-506, 2006. (Pubitemid 44136961)
34. Kimura Y and Okuda H: Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinomabearing mice. J Nutr 131: 1844-1849, 2001. (Pubitemid 32520456)
35. Busquets S, Ametller E, Fuster G, Olivan M, Raab V, et al: Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett 245: 144-148, 2007. (Pubitemid 44959346)
36. Weng YL, Liao HF, Li AF, Chang JC and Chiou RY: Oral administration of resveratrol in suppression of pulmonary metastasis of BALB/c mice challenged with CT26 colorectal adenocarcinoma cells. Mol Nutr Food Res 54: 259-267, 2010.
37. Kweon SH, Song JH and Kim TS: Resveratrol-mediated reversal of doxorubicin resistance in acute myeloid leukemia cells via downregulation of MRP1 expression. Biochem Biophys Res Commun 395: 104-110, 2010.
38. Harikumar KB, Kunnumakkara1 AB, Sethi G, Diagaradjane P, Anand P, et al: Resveratrol, a multitargeted agent, can enhance antitumor activity of gemcitabine in vitro and in orthotopic mouse model of human pancreatic cancer. Int J Cancer 127: 257-268, 2010.